O’Brien JA, Lahue BJ, Caro JJ, Davidson DM. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol. 2007:28(11):1219-1227.
Zhan C, Miller MR. Excess length of stay, charges and mortality attributable to medical injuries during hospitalization. JAMA. 2003;290(14):1868-1874.
HPIS. Q2 2011 data. Moving Annual Total (MAT) Fecal Control Category. Data on file, ConvaTec.
HCAI Technology Innovation Programme Showcase Hospitals report number 5. The Flexi-Seal® Fecal Management System. http://hcai.dh.gov.uk/files/2011/03/Evaluation_Report_Flexi_seal_faecal_management_system_HCAI_technologies_Dec09.pdf. Date accessed November 2011.
Keller BP, Wille J, van Ramshorst B, van der Werken C. Pressure ulcers in intensive care patients: a review of risks and prevention. Intensive Care Med. 2002;28(10):1379-1388.
Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. CID, 2002;34:346-53.
Popovich-Durnal A, Kommala D, Chen, Y. Budget Impact of Adopting a Fecal Management System in a Hospital Intensive Care Unit: A Single Center Experience. Poster presented at the Symposium on Advanced Wound Care Fall, Washington DC, September 2009.
AQUACEL® Ag Dressing is not a drug • In all of our silver products, the anti-microbial activity occurs within the dressing. The correlation between in vitro testing and clinical effectiveness has not been evaluated.